Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study
Uloženo v:
| Název: | Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study |
|---|---|
| Autoři: | Geert Maleux, Thomas Albrecht, Dirk Arnold, Irene Bargellini, Roberto Cianni, Thomas Helmberger, Frank Kolligs, Graham Munneke, Bora Peynircioglu, Bruno Sangro, Niklaus Schaefer, Helena Pereira, Bleranda Zeka, Niels de Jong, José I. Bilbao, Olivier D’Archambeau, Tugsan Balli, Sadik Bilgic, Allan Bloom, Roberto Cioni, Roman Fischbach, Patrick Flamen, Laurent Gerard, Rita Golfieri, Gerd Grözinger, Marcus Katoh, Michael Koehler, Jan Robert Kröger, Christiane Kuhl, Franco Orsi, Murat Özgün, Peter Reimer, Maxime Ronot, Axel Schmid, Alessandro Vit, Maciej Pech, Thomas Pfammatter |
| Přispěvatelé: | Repositorio de Navarra, CIRT Principal Investigators, Albrecht, T., D'Archambeau, O., Balli, T., Bilgic, S., Bloom, A., Cioni, R., Fischbach, R., Flamen, P., Gerard, L., Golfieri, R., Grözinger, G., Katoh, M., Koehler, M., Kröger, J.R., Kuhl, C., Orsi, F., Özgün, M., Reimer, P., Ronot, M., Schmid, A., Vit, A., Maleux, G., Sangro, B., Pech, M., Helmberger, T., Cianni, R., Pfammatter, T. |
| Zdroj: | Cardiovasc Intervent Radiol Dadun. Depósito Académico Digital de la Universidad de Navarra Universidad de Navarra Cardiovascular and interventional radiology, vol. 46, no. 7, pp. 852-867 |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2023. |
| Rok vydání: | 2023 |
| Témata: | Cardiac & Cardiovascular Systems, Carcinoma, Hepatocellular, MULTICENTER, Transarterial radioembolization, QUALITY-OF-LIFE, HEPATOCELLULAR-CARCINOMA, RADIATION-THERAPY, Humans, Liver tumour, Yttrium Radioisotopes, Carcinoma, Hepatocellular/radiotherapy, Carcinoma, Hepatocellular/pathology, Liver Neoplasms/therapy, Microspheres, Quality of Life, Yttrium Radioisotopes/adverse effects, Embolization, Therapeutic/adverse effects, Embolization, Therapeutic/methods, Europe/epidemiology, Colorectal Neoplasms/therapy, Predictors of adverse events, Clinical Investigation, 1102 Cardiorespiratory Medicine and Haematology, Science & Technology, Radiology, Nuclear Medicine & Medical Imaging, Liver Neoplasms, CANCER, Embolization, Therapeutic, 3. Good health, Europe, SORAFENIB, Nuclear Medicine & Medical Imaging, METASTASES, SELECTIVE INTERNAL RADIOTHERAPY, Cardiovascular System & Cardiology, SURVIVAL, CIRT Principal Investigators, 3201 Cardiovascular medicine and haematology, Colorectal Neoplasms, Life Sciences & Biomedicine, INDUCED LIVER-DISEASE |
| Popis: | Background Using data collected in the prospective observational study CIRSE Registry for SIR-Spheres Therapy, the present study aimed at identifying predictors of adverse events (AEs) following transarterial radioembolization (TARE) with Yttrium-90 resin microspheres for liver tumours. Methods We analysed 1027 patients enrolled between January 2015 and December 2017 and followed up for 24 months. Four hundred and twenty-two patients with hepatocellular carcinoma (HCC), 120 with intrahepatic carcinoma (ICC), 237 with colorectal liver metastases and 248 with liver metastases from other primaries were included. Prognostic factors were calculated with a univariable analysis by using the overall AEs burden score (AEBS). Results All-cause AEs were reported in 401/1027 (39.1%) patients, with AEs associated with TARE, such as abdominal pain (16.6%), fatigue (17%), and nausea (11.7%) reported most frequently. Grade 3 or higher AEs were reported in 92/1027 (9%) patients. Reports on grade ≥ 3 gastrointestinal ulcerations (0.4%), gastritis (0.3%), radiation cholecystitis (0.2%) or radioembolization-induced liver disease (0.5%) were uncommon. Univariable analysis showed that in HCC, AEBS increased for Eastern Cooperative Oncology Group (ECOG) 0 (p = 0.0045), 1 tumour nodule (0.0081), > 1 TARE treatment (p = 0.0224), no prophylactic embolization (p = 0.0211), partition model dosimetry (p = 0.0007) and unilobar treatment target (0.0032). For ICC, > 1 TARE treatment was associated with an increase in AEBS (p = 0.0224), and for colorectal liver metastases, ECOG 0 (p = 0.0188), > 2 prior systemic treatments (p = 0.0127), and 1 tumour nodule (p = 0.0155) were associated with an increased AEBS. Conclusion Our study confirms that TARE is a safe treatment with low toxicity and a minimal impact on quality of life. |
| Druh dokumentu: | Article Other literature type |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1432-086X 0174-1551 |
| DOI: | 10.1007/s00270-023-03391-4 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/36914788 https://hdl.handle.net/10171/68130 https://serval.unil.ch/notice/serval:BIB_753571631919 https://serval.unil.ch/resource/serval:BIB_753571631919.P001/REF.pdf http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_7535716319190 |
| Rights: | CC BY URL: http://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) . |
| Přístupové číslo: | edsair.doi.dedup.....ea0ea91f8862a3776354f92cb8cc3ba1 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Background Using data collected in the prospective observational study CIRSE Registry for SIR-Spheres Therapy, the present study aimed at identifying predictors of adverse events (AEs) following transarterial radioembolization (TARE) with Yttrium-90 resin microspheres for liver tumours. Methods We analysed 1027 patients enrolled between January 2015 and December 2017 and followed up for 24 months. Four hundred and twenty-two patients with hepatocellular carcinoma (HCC), 120 with intrahepatic carcinoma (ICC), 237 with colorectal liver metastases and 248 with liver metastases from other primaries were included. Prognostic factors were calculated with a univariable analysis by using the overall AEs burden score (AEBS). Results All-cause AEs were reported in 401/1027 (39.1%) patients, with AEs associated with TARE, such as abdominal pain (16.6%), fatigue (17%), and nausea (11.7%) reported most frequently. Grade 3 or higher AEs were reported in 92/1027 (9%) patients. Reports on grade ≥ 3 gastrointestinal ulcerations (0.4%), gastritis (0.3%), radiation cholecystitis (0.2%) or radioembolization-induced liver disease (0.5%) were uncommon. Univariable analysis showed that in HCC, AEBS increased for Eastern Cooperative Oncology Group (ECOG) 0 (p = 0.0045), 1 tumour nodule (0.0081), > 1 TARE treatment (p = 0.0224), no prophylactic embolization (p = 0.0211), partition model dosimetry (p = 0.0007) and unilobar treatment target (0.0032). For ICC, > 1 TARE treatment was associated with an increase in AEBS (p = 0.0224), and for colorectal liver metastases, ECOG 0 (p = 0.0188), > 2 prior systemic treatments (p = 0.0127), and 1 tumour nodule (p = 0.0155) were associated with an increased AEBS. Conclusion Our study confirms that TARE is a safe treatment with low toxicity and a minimal impact on quality of life. |
|---|---|
| ISSN: | 1432086X 01741551 |
| DOI: | 10.1007/s00270-023-03391-4 |